Consultation responses on the future reimbursement status of medicinal products for cardiovascular diseases
The Reimbursement Committee’s additional recommendation concerning the future reimbursement status of medicinal products for cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09 (antihypertensives) was submitted for consultation with 19 September 2008 as the consultation deadline.
The Danish Medicines Agency has received nine consultation responses. Of these, five were submitted by companies, two by scientific societies, one by a patient organisation and one by others. In the factbox to the right, there is a link to the consultation responses (in Danish only). Here, you can also find a link to the Danish Medicines Agency’s message of 4 September 2008 containing the Reimbursement Committee’s additional recommendation.
The Danish Medicines Agency has requested the Reimbursement Committee to comment on the submitted consultation responses, and the Danish Medicines Agency will resume its consideration of the case.
For further information, please contact the Reimbursement Department at email@example.com.
Danish Medicines Agency, 21 October 2008